TrialCompass TCL
Back to results
RecruitingPriority 4 · Lower priorityNCT07021495

SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)

ClinicalTrials.gov

Plain-language summary

This trial is studying a new treatment for people with cutaneous T-cell lymphoma (skin lymphoma). The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join (key eligibility)

  • Age 18 Years or older
  • May require specific number of prior treatments

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Drugs / treatments
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)

NCT07021495

Phase: | Status: Recruiting | Priority: Lower

Plain-language summary

This trial is studying a new treatment for people with cutaneous T-cell lymphoma (skin lymphoma). The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join

  • Age 18 Years or older
  • May require specific number of prior treatments

What's being tested

Drugs / treatments:

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, blind

Enrollment target: 840 patients

Primary endpoint: Lipidomics of the stratum corneum and OLINK; Cutaneous microbiome; Serum biomarkers; Plasma biomarkers; Eczema Area and Severity Index (EASI); objective Severity Scoring of Atopic Dermatitis (oSCORAD); Validated Investigator Global Assessment scale for Atopic Dermatitis (vIGA-AD); Cutaneous LE Disease Area and Severity Index Activity (CLASI-A); Total Sum Score; The Cutaneous Lupus Activity-Investigator Global Assessment (CLA-IGA); International Hidradenitis Suppurativa Severity Score System (IHS4); Modified Severity-Weighted Assessment Tool (mSWAT); Cutaneous Lymphoma Activity and Severity Index (CAILS); Psoriasis Area and Severity Index (PASI); Physician Global Assessment (PGA); Body Surface Area (BSA); Psoriasis Area and Severity Index - High Discrimination (PASI-HD)

Ages: 18 Years to —

Start date: 2025-07-29 | Est. completion: 2029-12-31

Locations

0 US sites · 8 total

Contact

Robert Rissmann, Professor | r.rissmann@lumc.nl | +31 71 526 9111

Sponsor: Leiden University Medical Center (OTHER)

Tags

CTCL · any

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT07021495

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.